• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特发性肺纤维化中的肺动脉高压与肺功能测试

Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis.

作者信息

Nathan Steven D, Shlobin Oksana A, Ahmad Shahzad, Urbanek Susan, Barnett Scott D

机构信息

Inova Fairfax Hospital, Falls Church, VA.

Inova Fairfax Hospital, Falls Church, VA.

出版信息

Chest. 2007 Mar;131(3):657-663. doi: 10.1378/chest.06-2485.

DOI:10.1378/chest.06-2485
PMID:17356077
Abstract

BACKGROUND

Pulmonary hypertension (PH) is commonly seen in patients with idiopathic pulmonary fibrosis (IPF). We sought to examine the relationship between pulmonary function tests (PFTs), including the percentage of predicted FVC (FVC%), percentage of predicted total lung capacity, percentage of predicted diffusing capacity of the lung for carbon monoxide (Dlco%), the composite physiologic index (CPI), and PH. The ability of FVC%, Dlco%, and FVC%/Dlco% ratio to predict underlying PH was assessed.

METHODS

Retrospective review of IPF patients seen at a tertiary referral center over an 8-year interval in whom both PFT and right-heart catheterization data were available.

RESULTS

The study cohort consisted of 118 patients, of whom 48 patients (40.7%) had PH. There was no correlation between measures of lung volumes or the CPI with underlying PH. There was a modest association between Dlco% and PH, with Dlco% < 30 having a twofold-higher prevalence of PH (56.4%) compared to Dlco% >/= 30 (28.6%). Cardiac dysfunction might have played a small role, since 16.1% of the patients had an associated elevated pulmonary capillary wedge pressure. There was a trend to a higher prevalence and greater severity of PH in those patients with FVC% > 70 compared to the group with FVC% < 40.

CONCLUSION

PH is common in patients with IPF. There is a poor correlation between lung function measures and PH, suggesting that factors other than fibrosis may play a role in the etiology. The unexpected high prevalence and severity of PH in patients with well-maintained lung function have implications for the prognosis and management of the disease.

摘要

背景

肺动脉高压(PH)在特发性肺纤维化(IPF)患者中很常见。我们试图研究肺功能测试(PFTs),包括预测用力肺活量百分比(FVC%)、预测肺总量百分比、预测一氧化碳弥散量百分比(Dlco%)、综合生理指数(CPI)与PH之间的关系。评估了FVC%、Dlco%和FVC%/Dlco%比值预测潜在PH的能力。

方法

回顾性分析在一家三级转诊中心8年间诊治的IPF患者,这些患者同时有PFT和右心导管检查数据。

结果

研究队列包括118例患者,其中48例(40.7%)有PH。肺容积测量指标或CPI与潜在PH之间无相关性。Dlco%与PH之间存在适度关联,Dlco%<30的PH患病率(56.4%)是Dlco%≥30者(28.6%)的两倍。心脏功能障碍可能起了较小作用,因为16.1%的患者伴有肺毛细血管楔压升高。与FVC%<40的患者相比,FVC%>70的患者中PH患病率更高、病情更严重,存在这一趋势。

结论

PH在IPF患者中很常见。肺功能指标与PH之间相关性较差,提示除纤维化外的其他因素可能在病因中起作用。肺功能良好的患者中PH意外的高患病率和严重程度对该疾病的预后和管理有影响。

相似文献

1
Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis.特发性肺纤维化中的肺动脉高压与肺功能测试
Chest. 2007 Mar;131(3):657-663. doi: 10.1378/chest.06-2485.
2
Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis.肺动脉压和肺弥散能力作为特发性肺纤维化患者预后指标的意义
Chest. 2007 Mar;131(3):650-656. doi: 10.1378/chest.06-1466. Epub 2007 Feb 22.
3
Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography.特发性肺纤维化:一种源自计算机断层扫描所观察到的疾病范围的综合生理指标。
Am J Respir Crit Care Med. 2003 Apr 1;167(7):962-9. doi: 10.1164/rccm.2111053.
4
Pulmonary hypertension in chronic lung diseases.慢性肺部疾病相关肺动脉高压。
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D109-16. doi: 10.1016/j.jacc.2013.10.036.
5
Does reduced lung diffusing capacity for carbon monoxide predict the presence of pulmonary hypertension?一氧化碳肺弥散量降低能否预测肺动脉高压的存在?
Am J Med Sci. 2010 Jul;340(1):54-9. doi: 10.1097/MAJ.0b013e3181dd1a89.
6
Pulmonary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress.特发性肺纤维化中的肺动脉高压:患病率和临床进展。
Int J Immunopathol Pharmacol. 2012 Jul-Sep;25(3):681-9. doi: 10.1177/039463201202500314.
7
Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis.特发性肺纤维化初始评估中肺动脉高压作为预后指标。
Respiration. 2013;85(6):456-63. doi: 10.1159/000345221. Epub 2012 Dec 19.
8
Influence of radiological emphysema on lung function test in idiopathic pulmonary fibrosis.放射性肺气肿对特发性肺纤维化肺功能检查的影响。
Respir Med. 2013 Nov;107(11):1781-8. doi: 10.1016/j.rmed.2013.08.039. Epub 2013 Sep 3.
9
Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide.慢性肺部疾病导致肺动脉高压患者的生存率:一氧化碳肺弥散量降低的影响。
J Heart Lung Transplant. 2019 Feb;38(2):145-155. doi: 10.1016/j.healun.2018.09.011. Epub 2018 Sep 14.
10
Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis.特发性肺纤维化中肺动脉高压的预测
Respir Med. 2007 Oct;101(10):2153-9. doi: 10.1016/j.rmed.2007.05.012. Epub 2007 Jul 2.

引用本文的文献

1
Comorbidities' Effect on IPF: Pathogenesis and Management.合并症对特发性肺纤维化的影响:发病机制与管理
Biomedicines. 2025 Jun 1;13(6):1362. doi: 10.3390/biomedicines13061362.
2
A Twist in the Fibrotic Tale: The Overlooked Vasculopathy in Idiopathic Pulmonary Fibrosis.纤维化故事中的一个转折:特发性肺纤维化中被忽视的血管病变
Am J Respir Crit Care Med. 2025 Jun;211(6):897-898. doi: 10.1164/rccm.202502-0465ED.
3
Association of tracheal diameter with respiratory function and fibrosis severity in idiopathic pulmonary fibrosis patients.
特发性肺纤维化患者气管直径与呼吸功能及纤维化严重程度的相关性
BMC Pulm Med. 2025 Apr 5;25(1):157. doi: 10.1186/s12890-025-03624-x.
4
Serial Pulmonary Hemodynamics in Patients with Idiopathic Pulmonary Fibrosis Listed for Lung Transplant.等待肺移植的特发性肺纤维化患者的系列肺血流动力学研究
Am J Respir Crit Care Med. 2025 Jun;211(6):984-991. doi: 10.1164/rccm.202411-2157OC.
5
Performance of the FORD Versus Other Available Models for the Noninvasive Prediction of Pulmonary Hypertension in Patients with Interstitial Lung Disease.FORD模型与其他可用模型在间质性肺疾病患者肺动脉高压无创预测中的性能比较
Lung. 2025 Jan 22;203(1):27. doi: 10.1007/s00408-024-00783-2.
6
Screening and diagnosis of pulmonary hypertension associated with chronic lung disease (PH-CLD): A consensus statement from the pulmonary vascular research institute's innovative drug development initiative-group 3 pulmonary hypertension.慢性肺病相关肺动脉高压(PH-CLD)的筛查与诊断:肺血管研究所创新药物开发倡议-3型肺动脉高压共识声明
Pulm Circ. 2024 Dec 10;14(4):e70005. doi: 10.1002/pul2.70005. eCollection 2024 Oct.
7
Burden of illness in patients with pulmonary hypertension due to interstitial lung disease: a real-world analysis.特发性肺纤维化相关肺动脉高压患者的疾病负担:真实世界分析。
BMC Pulm Med. 2024 Jul 11;24(1):335. doi: 10.1186/s12890-024-03141-3.
8
Pulmonary vascular dysfunction without pulmonary hypertension: A distinct phenotype in idiopathic pulmonary fibrosis.无肺动脉高压的肺血管功能障碍:特发性肺纤维化的一种独特表型。
Pulm Circ. 2024 Jan 3;14(1):e12311. doi: 10.1002/pul2.12311. eCollection 2024 Jan.
9
Pulmonary Hypertension in Interstitial Lung Disease: Updates in Disease, Diagnosis, and Therapeutics.特发性肺纤维化相关肺动脉高压:疾病、诊断和治疗的最新进展。
Cells. 2023 Oct 1;12(19):2394. doi: 10.3390/cells12192394.
10
Impact of targeted pulmonary arterial hypertension therapies in severe pulmonary hypertension in chronic lung diseases.靶向肺动脉高压疗法对慢性肺部疾病严重肺动脉高压的影响。
ERJ Open Res. 2023 Aug 21;9(4). doi: 10.1183/23120541.00027-2023. eCollection 2023 Jul.